The market size for COPD in the US was estimated to be about $18.6bn in 2023 while the size of the asthma market in the country was approximately $7.2bn in the same year, according to GlobalData’s Pharma Intelligence Centre.
While the upcoming trials will focus on these two diseases, Uniquity suggested the antibody could have applications in a wide range of immunology and inflammation programmes.
Uniquity CEO Brian Lortie said solrikitug “has the potential to be a life-changing medication for a significant number of patients who currently have very limited treatment options”, and that the company is “excited to move into the next phase of development.”
Uniquity gave no further details on the timings of the upcoming Phase II trials. But Blackstone Life Sciences’ global head Nicholas Galakatos reckons that the advancement of solrikitug will accompany an expanding pipeline for startups.
Galakatos said: “We are proud to partner with Uniquity’s team of veteran industry leaders as they advance solrikitug and expand their immunology and inflammation pipeline with additional programs in the near future.”
Immunology and inflammation are two of the hot areas to be a part of in the current pharma landscape. In February, inflammatory disease specialist Aiolos Bio was acquired by GSK in a $1.4bn deal. Aiolos had launched not long before in October 2023 with $200m and a monoclonal antibody that also targeted TSLP.
Also in the space is Mirador Therapeutics which launched in late March 2024. Ushered in by the former head of MSD-bought Prometheus, the company secured $400m in Series A financing.